MUDr. Eva Dokoupilová, Ph.D., MBA

Fojtík, Z., Řehák, Z., Šimíková, J., Kielkowská, I., Dokoupilová, E. Non-invasive imaging in the diagnosis of large vessel vasculitis. Scand. J. Rheumatol., 2006, vol. 35, supl. 121, p. 52.

Distler, O., Eich, W., Dokoupilova, E., Dvorak, Z., Fleck, M., Gaubitz, M., Hechler, M., Jansen, J.P., Krause, A., Bendszus, M., Pache, L., Reiter, R., Müller-Ladner, U. Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism. 2010, vol. 62, no. 1, p. 291–300.

Branco, J.C., Zachrisson, O., Perrot, S., Mainguy, Y.; Multinational Coordinator Study Group, Collaborators: Klanova, I., Polivka, J., Svoboda, P., Dokoupilova, E., Danneskiold-Samsoe, B., Hannonen, .P, Kouri, J.P., Lehtonen-Veromaa, M., Partinen, M., Auvinet, B., Baron, D., Cherin, P., Courtheoux, F., Delorme, C., Dumolard, A., Picard, P., Hatron, P.Y., Lanteri-Minet, M., Maugars, Y., Mejjad, O., Schalck, R., Rioult, B., Roussel, P., Serra, E., Viel, E., Mazieres, B., Ginies, P., Cantagrel, N., De Korwin, J.D., Ginesty, E., Nadstawek, J., Neeck, G., Späth, M., Alten, R., Bolten, W., Bianchi, G., Biasi, G., Bombardieri, S., Cazzola, M., Cimmino, M.A., Fantini, F., Punzi, L., Venditti, C., Trotta, F., Matucci Cerinic, M., Grassi, W., Ofjord, S., Knudsrod, O., Szczepanski, L., Targonska-Stepniak, B., Szechiński, J., Araujo, D., Figueiredo, G., Tavares, V., Paiva, T., Cruz, M., Bolosiu, H., Codreanu, C., Ionescu, R., Radulescu, F., Suta, M., Collado, A., Alegre, C., Rivera, J., Rodriguez de la Serna, A., Riestra, J.L., Vidal, J., De Teresa, L., Petersson, I., Bragee, B., Sörensen, J., Walker, D. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. The Journal of Rheumatology. 2010, vol. 37, no. 4, p. 851–859.

Dokoupilova, E. Úspěch biologické léčby u revmatoidní artritidy. Medical Tribune. 2011, vol. 7, no. 8, 2 p.

Durez, P., Genovese, C. G., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., Lee, S.-H., Codding, C. E., Kellner, H., Ikawa, T., Hugot, S., Ligozio, G. and Mpofu, S. Secukinumab Treatment Provides Sustained Response Over One Year in Patients with Rheumatoid Arthritis. Congress Rheumatology 2012.

Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Mazurov, V., Aelion, J. A., Lee, S.-H., Codding, C. E., Kellner, H., Ikawa, T., Hugot, S., Mpofu, S., FRCP. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomized, placebo-controlled study. Annals of the Rheumatic Diseases. 2012.

Genovese, M.C., Durez, P., Richards, H.B., Supronik, J., Dokoupilova, E., Mazurov, V., Aelion, J.A., Lee, S.H., Codding, C.E., Kellner, H., Ikawa, T., Hugot, S., Mpofu, S. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.Annals of the Rheumatic Diseases [online]. 2013, 72(6), 863-869.

Genovese, M.C., Durez, P., Richards, H.B., Supronik, J., Dokoupilova, E., Aelion, J.A., Lee, S.H., Codding, C.E., Kellner, H.,Ikawa, T., Hugot, S., Ligozio, G., Mpofu, S. One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. The Journal of Rheumatology [online]. 2014, 41(3), 414-421.

Šenolt, L., Leszyzynski, P., Dokoupilova, E., Göthberg, M., Valencia, X., Hansen, B. B., Caete, J. D. Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. Arthritis & Rheumatology [online]. 2015, 67(6), 1438-1448.

Pavelka, Karel, Alan Kivitz, Eva Dokoupilova, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Research & Therapy [online]. 2017, 19(1).

Blanco, Francisco J., Rüdiger Möricke, Eva Dokoupilova, Christine Codding, Jeffrey Neal, Mats Andersson, Susanne Rohrer A Hanno Richards. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. Arthritis & Rheumatology [online]. 2017, 69(6), 1144-1153.

Dokoupilová, E., J Aelion, T Takeuchi, N Malavolta, Pp Sfikakis, Y Wang, S Rohrer A Hb Richards. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis. Scandinavian Journal of Rheumatology [online]. 2018, , 1-6.

Weinblatt, Michael E., Asta Baranauskaite, Eva Dokoupilova, et al. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology [online]. 2018, 70(6), 832-840.

Kivitz, Alan J., Ulf Wagner, Eva Dokoupilova, Jerzy Supronik, Ruvie Martin, Zsolt Talloczy, Hanno B. Richards A Brian Porter. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study. Rheumatology and Therapy [online]. 2018, 5(2), 447-462.

Sudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, Ulf Müller Ladner, Meera Ramanujam, Bernd Rosenstock, Anastasia G Eleftheraki, Richard Vinisko, Alena Petříková, Herbert Kellner, Eva Dokoupilova, Brdygida Kwiatkowska, Rie e Alten, Christian Schwabe, Patrick Baum, David Joseph, Jay S Fine, Steven J Padula, Jȕrgen Steffgen. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study Annals of the Rheumatic Diseases. Jun 2019, 78 (6) 754-760.

Mark C. Genovese, Josephine Glover, Maria Greenwald, Wieslawa Porawska, Elias Chalouhi El Khouri, Eva Dokoupilova, Juan Ignacio Vargas, Mykola Stanislavchuk, Herbert Kellner, Elena Baranova, Nobuhito Matsunaga and Rieke Alten. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Research & Therapy 2019, 21:281.

Karel Pavelka, Alan J. Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O. Porter, Anna Stefanska, Hanno B. Richards, and Susanne Rohrer, on behalf of the MEASURE 3 study group. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatology Vol. 0, No. 0, Month 2020, pp 1–9.

Karel Pavelka, Andrea Bernetti, Nicola Giordan, Eva Dokoupilová, Valter Santilli. Dose-response of hyaluronate-based viscoelastic hydrogels for the treatment of knee osteoarthrosis: a prospective, randomized, comparative clinical trial. Minerva Ortopedica e Traumatologica. 2020 June;71(2):45-55.

Wiland P, Jeka S, Dokoupilová E, et al. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. BioDrugs. 2020;34(6):809-823.

Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. Arthritis Rheumatol. 2021;73(1):110-120.

VETCHÝ, D., PAVLOKOVÁ, S., VETCHÁ, M., DOKOUPILOVÁ, E. Adalimumab a infliximab – porovnání originálních a biosimilárních léků pomocí vícerozměrné analýzy dat. Farmakoterapie. 2018;14(suppl. 7):8–12.

DOKOUPILOVÁ, E., AELION, J., TAKEUCHI, T., MALAVOLTA, N., SFIKAKIS, P., WANG, Y., RICHARDS, H. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis. Scandinavian Journal of Rheumatology. 2018; 47(4): 276–281. https://doi.org/10.1080/03009742.2017.1390605
Q3, IF₂₀₂₃2, Number of Citation: 33

SMOLEN, J.S., CHOE, J.Y., PRODANOVIC, N., NIEBRZYDOWSKI, J., STAYKOV, I., DOKOUPILOVA, E., BARANAUSKAITE, A., YATSYSHYN, R., MEKIC, M., PORAWSKA, W., CIFERSKA, H., JEDRYCHOWICZ-ROSIAK, K., ZIELINSKA, A., LEE, Y., RHO, Y.H. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018 Feb;77(2):234-240. doi: 10.1136/annrheumdis-2017-211741.
Q1, IF₂₀₂₃3, Number of Citation: 95

NASH, P., MEASE, P.J., MCINNES, I.B. et al.Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018; 20: 47. https://doi.org/10.1186/s13075-018-1551-x
Q1, IF₂₀₂₃4, Number of Citation: 128

WEINBLATT, M.E., BARANAUSKAITE, A., DOKOUPILOVA, E., ZIELINSKA, A., JAWORSKI, J., RACEWICZ, A., PILECKYTE, M., JEDRYCHOWICZ-ROSIAK, K., BAEK, I. AND GHIL, J. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2018; 70: 832-840. https://doi.org/10.1002/art.40444
Q1, IF₂₀₂₃4, Number of Citation: 97

GENOVESE, M. C., GLOVER, J., GREENWALD, M., PORAWSKA, W., CHALOUHI EL KHOURI, E., DOKOUPILOVA, E., VARGAS, J. I., STANISLAVCHUK, M., KELLNER, H., BARANOVA, E., MATSUNAGA, N. AND ALTEN, R. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Research & Therapy. 2019, 21:281.
Q1, IF₂₀₂₃4, Number of Citation: 38

PAVELKA, K., BERNETTI, A., GIORDAN, N., DOKOUPILOVÁ, E., SANTILLI, V. Dose-response of hyaluronate-based viscoelastic hydrogels for the treatment of knee osteoarthrosis: a prospective, randomized, comparative clinical trial. Minerva Ortopedica e Traumatologica. 2020 June;71(2):45-55.

PAVELKA, K., KIVITZ, A. J., DOKOUPILOVA, , BLANCO, R., MARADIAGA, M., TAHIR, H., WANG, Y., PORTER, B. O., STEFANSKA, A., RICHARDS, H. B.  AND ROHRER, S. on behalf of the MEASURE 3 study group. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatology Vol. 2, No. 2, February 2020, pp 119 – 127.

PELLETIER, J. P., J. P. RAYNAULD, M. DORAIS, L. BESSETTE,  DOKOUPILOVÁ, E., F. MORIN, K. PAVELKA, P. PAIEMENT a J. MARTEL-PELLETIER. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. RHEUMATOLOGY. OXFORD: OXFORD UNIV PRESS, 2020, roč. 59, č. 12, s. 3858-3868. ISSN 1462-0324. Dostupné z: https://dx.doi.org/10.1093/rheumatology/keaa072.
Q1, IF₂₀₂₃7, Number of Citation: 22

WILAND, P., S. JEKA, DOKOUPILOVÁ, E., J. BRANDT-JURGENS, J. M. M. LIMON, M. C. MOREIRA, R. V. CABELLO, J. JAUCH-LEMBACH, A. THAKUR, H. HALIDUOLA, I. BRUECKMANN a N. B. GAYLIS. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. BIODRUGS. NORTHCOTE: ADIS INT LTD, 2020, roč. 34, č. 6, s. 809-823. ISSN 1173-8804. Dostupné z: https://dx.doi.org/10.1007/s40259-020-00447-6.
Q1, IF₂₀₂₃4, Number of Citation: 29

ORBAI, A.M., J. GRATACOS, A. TURKIEWICZ, S. HALL, DOKOUPILOVÁ, E., B. COMBE, P. NASH, G. GALLO, C.C. BERTRAM, A.M. GELLETT, A. T. SPRABERY, J. BIRT, L. MACPHERSON, V.J. GENEUS a A. CONSTANTIN. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). RHEUMATOLOGY AND THERAPY. NEW YORK: SPRINGER, 2020, roč. 8, č. 1, s. 199-217. ISSN 2198-6576. Dostupné z: https://dx.doi.org/10.1007/s40744-020-00261-0.
Q2, IF₂₀₂₃9, Number of Citation: 9

MEASE, P.J., A. LERTRATANAKUL, K.A. PAPP, F.E. VAN DEN BOSCH, S. TSUJI, DOKOUPILOVÁ, E., M.W. KEISERMAN, X.W. BU, L. CHEN, R.M. MCCASKILL, P. ZUEGER, E.L. MCDEARMON-BLONDELL, A.L. PANGAN a W. TILLETT. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. RHEUMATOLOGY AND THERAPY. NEW YORK: SPRINGER, 2021, roč. 8, č. 2, s. 903-919. ISSN 2198-6576. Dostupné z: https://dx.doi.org/10.1007/s40744-021-00305-z.
Q1, IF₂₀₂₃3, Number of Citation: 90

FLEISCHMANN, R. M., BOCK, A. E., ZHANG, W., GODFREY, C. M., VRANIC, I., CRONENBERGER, C., DOKOUPILOVÁ, E. Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. RHEUMATOLOGY AND THERAPY. NEW YORK: SPRINGER, 2022, roč. 9, č. 3, s. 839-850. ISSN 2198-6576. Dostupné z: https://dx.doi.org/10.1007/s40744-022-00439-8.
Q2, IF₂₀₂₃9, Number of Citation: 3

BEHRENS, F., SEWERIN, P., Eugenio DE, M., PATEL, Y., BATALOV, A., DOKOUPILOVÁ, E., KLEINMOND, C., POURNARA, E., SHEKHAWAT, A., JENTZSCH, C., WIEDON, A., BARALIAKOS, X. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial. RHEUMATOLOGY. OXFORD: OXFORD UNIV PRESS, 2022, Neuveden., November, s. 1-11. ISSN 1462-0324. Dostupné z: https://dx.doi.org/10.1093/rheumatology/keab784.
Q1, IF₂₀₂₃7, Number of Citation: 9

JEKA, S., DOKOUPILOVÁ, E., KIVITZ, A., ZUCHOWSKI, P., VOGG, B., KRIVTSOVA, N., SEKHAR, S., BANERJEE, S., SCHWEBIG, A., POETZL, J., BODY, J.-J., EASTELL, R. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. Journal of bone and mineral research. Hoboken: Wiley, 2024, roč. 39, č. 3, s. 202-210. ISSN 0884-0431. Dostupné z: https://dx.doi.org/10.1093/jbmr/zjae016.
Q1, IF₂₀₂₃1, Number of Citation: 0

DOKOUPILOVÁ, E.,  VETCHÝ, D., PAVLOKOVÁ, S., HANUŠTIAKOVÁ, M.. Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. NETHERLANDS: SPRINGER, 2024, Neuveden, č. 7, s. 1-10. ISSN 2210-7703. Dostupné z: https://dx.doi.org/10.1016/j.ijpx.2024.100229.
Q1, IF₂₀₂₃2, Number of Citation: 0

LANGDAHL, B., CHUNG, Y.-S., PLEBANSKI, R., CZERWINSKI, E., DOKOUPILOVA, E., SUPRONIK, J., ROSA, J., MYDLAK, A., ROWIŃSKA-OSUCH, A., BAEK, K.-H., URBONIENE, A., MORDAKA, R., AHN, S., RHO, Y. H., BAN, J., EASTELL, R. Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12, The Journal of Clinical Endocrinology & Metabolism, 2024; dgae611, https://doi.org/10.1210/clinem/dgae611
Q1, IF₂₀₂₃ 5, Number of Citation: 0

EASTELL, R., LANGDAHL, B., CHUNG, Y.S., et al POS0085 A Randomized, Double-Blind, Phase Iii Study To Compare Sb16 (Proposed Denosumab Biosimilar) To Reference Denosumab In Patients With Postmenopausal Osteoporosis: 18-Month Results. Annals of the Rheumatic
Diseases. 2024;83:490.

KIVITZ, A., MUENSTERMAN, E.T., KAVANAUGH, A., et al. OP0138 Efficacy And Safety Outcomes Of Tak-279, A Selective Oral Tyrosine Kinase 2 (Tyk2) Inhibitor, From A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial In Patients With Active Psoriatic Arthritis. Annals of the Rheumatic Diseases; 2024;83:149-151.

GOTTLIEB, A., MUENSTERMAN, E., KIVITZ, A., DOKOUPILOVA, E., LERTRATANAKUL, A., HONG, T., CHEN, J., BARALIAKOS, X. Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9)

CHOE, J.-Y.; PRODANOVIC, N.; NIEBRZYDOWSKI, J.; STAYKOV, I.; DOKOUPILOVA, E. et al. SAT0152 A Randomised, Double-Blind, Phase III Study Comparing SB2, An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy. Online. Annals of the Rheumatic Diseases. 2015, roč. 74, s. 706-707. ISSN 00034967. Dostupné z: https://doi.org/10.1136/annrheumdis-2015-eular.1583.

RAHMAN, P.; STRAND, V.; MCINNES, I.B.; MARZO-ORTEGA, H.; DOKOUPILOVÁ, E. et al. THU0433 Secukinumab Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in Future 2, A Phase 3 Trial. Online. Annals of the Rheumatic Diseases. 2015, roč. 74. ISSN 00034967.

DANILUK, S.; PTASZYNSKI, R.; MUELLER-LADNER, U.; PETRIKOVA, A.; KELLNER, H. et al. SAT0147 Safety and Efficacy of BI 655064, An Antagonistic Anti-CD40 Antibody in Rheumatoid Arthritis (RA) Patients. Online. Annals of the Rheumatic Diseases. 2016, roč. 75. ISSN 00034967. Dostupné z: https://doi.org/10.1136/annrheumdis-2016-eular.1271.

SMOLEN, J.S.; CHOE, J.-Y.; PRODANOVIC, N.; NIEBRZYDOWSKI, J.; STAYKOV, I. et al. FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study. Online. Annals of the Rheumatic Diseases. 2016, roč. 75. ISSN 00034967. Dostupné z: https://doi.org/10.1136/annrheumdis-2016-eular.3122.

WEINBLATT, M.; BARANAUSKAITE, A.; NIEBRZYDOWSKI, J.; DOKOUPILOVA, E.; ZIELINSKA, A. et al. FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study. Online. Annals of the Rheumatic Diseases. 2016, roč. 75. ISSN 00034967. Dostupné z: https://doi.org/10.1136/annrheumdis-2016-eular.1762.

LANGDAHL, B.; LIBANATI, C.; CRITTENDEN, D.; BOLOGNESE, M.; BROWN, J. et al. OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study. Online. Annals of the Rheumatic Diseases. 2016, roč. 75, s. 92-93. ISSN 00034967. Dostupné z: https://doi.org/10.1136/annrheumdis-2016-eular.1163.

ALTEN, R.; TSELUYKO, V.; HALA, T.; MEHMEDAGIC, S.; PILECKYTE, M. et al. FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. Online. Annals of the Rheumatic Diseases. 2018, roč. 77, s. 612-613. ISSN 00034967. Dostupné z: https://doi.org/10.1136/annrheumdis-2018-eular.5121.

WILAND, Piotr; JEKA, Sławomir; DOKOUPILOVA, Eva; MIRANDA LIMON, Juan Manuel; JAUCHLEMBACH, Julia et al. FRI0087 EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB (REFADL) TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZADL)
FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA). Online. Annals of the Rheumatic Diseases. 2019, roč. 78, s. 706-707. ISSN 00034967.

GENOVESE, M. C., LERTRATANAKUL, A. ,  ANDERSON, J., PAPP, K., TILLETT, W., VAN DEN BOSCH, F., TSUJI, S., DOKOUPILOVA, E., KEISERMAN, M., WANG, X., ZHONG, S., ZUEGER, P., PANGAN, A., MEASE, P. J. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2): a doubleblind, randomized controlled phase 3 trial. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 139.

GRATACOS-MASMITJA, J., TURKIEWICZ, A., DOKOUPILOVA, E., GELLETT, A. M., SPRABERY, A. T., GENEUS, V. J., CONSTANTIN, A. Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to tnf inhibitors: three year results from a phase 3 study (SPIRIT-P2). Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1154.

BRAUN, J., BLANCO, R., DOKOUPILOVA, E., GENSLER, L. S., KIVITZ, A., HALL, S., KAMEDA, H., PODDUBNYY, D., VAN DE SANDE, M., VAN DER HEIJDE, D., WIKSTEN, A., PORTER, B., RICHARDS, H., HAEMMERLE, S. , DEODHAR, A. Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase 3 prevent study. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 69.

ORBAI, A. M., GRATACOS-MASMITJA, J., DOKOUPILOVA, E., COMBE, B., CONSTANTIN, A., GELLETT, A. M., SPRABERY, A. T., BIRT, J., GENEUS, V., NASH, P. Sustained improvements in physical function, quality of life, and work productivity with ixekizumab in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors: 3-year results from SPIRIT-P2 trial. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1705.

PODDUBNYY, D., DEODHAR, A., BARALIAKOS, X., BLANCO, R., DOKOUPILOVÁ, E., HALL, S. KIVITZ, A.,  VAN DE SANDE, M.G.H.,  STEFANSKA, A., PERTEL, P., RICHARDS H., BRAUN, J. Secukinumab 150 mg provides sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis: 2-year results from the PREVENT STUDY. 2021. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2021-eular.143.

MEASE, P.J., LERTRATANAKUL, A., PAPP, K., VAN DEN BOSCH, F., TSUJI, S., DOKOUPILOVÁ, E., KEISERMAN, M., BU, X., CHEN, L., MCCASKILL, R., ZUEGER, P., MCDEARMON-BLONDELL, E., PANGAN, A. TILLETT, W. Upadacitinib in patients with psoriatic arthritis refractory to biologic disease-modifying antirheumatic drugs: 56-week data from the phase 3 SELECT-PSA 2 STUDY. 2021. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2021-eular.1066.

GENOVESE, M. C., LERTRATANAKUL, A. , ANDERSON, J., PAPP, K., TILLETT, W., VAN DEN BOSCH, F., TSUJI, S., DOKOUPILOVÁ, E., KEISERMAN, M., WANG, X., ZHONG, S., ZUEGER, P., PANGAN, A., MEASE, P. J. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2). 2020. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2020-eular.1229.

DEODHAR, A., BLANCO, R., DOKOUPILOVÁ, E., VAN DE SANDE, M., HALL, A. WIKSTEN, B. O. PORTER, H. O. RICHARDS, S. HAEMMERLE a J. BRAUNS. Secukinumab significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 16-week results from the phase-iii PREVENT STUDY. 2020.

BEHRENS, F., TAYLOR, P. C., WETZEL, D., BRUN, N. C., BRANDT-JUERGENS, J., DRESCHER, E., DOKOUPILOVÁ, E., ROWINSKA-OSUCH, A., MARTIN, N. A.-K., DE VLAM, K. IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY. 2022. ISSN 0003-4967. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2022-eular.536.

EASTELL, R.; LANGDAHL, B.; CHUNG, Y.S.; PLEBANSKI, R.; CZERWINSKI, E. et al. POS0085 A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY TO COMPARE SB16 (PROPOSED DENOSUMAB BIOSIMILAR) TO REFERENCE DENOSUMAB IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS: 18-MONTH RESULTS. Online. Annals of the Rheumatic Diseases. 2024, roč. 83. ISSN 00034967. Dostupné z: https://doi.org/10.1136/annrheumdis-2024-eular.188.

KIVITZ, A.; MUENSTERMAN, E.T.; KAVANAUGH, A.; VAN DER HEIJDE, D.; KLIMIUK, P.A. et al. OP0138 EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Online. Annals of the Rheumatic Diseases. 2024, roč. 83, s. 149-151. ISSN 00034967. Dostupné z: https://doi.org/10.1136/annrheumdis-2024-eular.351.

DEODHAR, A., BLANCO, R., DOKOUPILOVA, E., VAN DE SANDE, M., HALL, S., WIKSTEN, A. S., PORTER, B. O., RICHARDS, H. B., HAEMMERLE, S., BRAUN, J. Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondylosrthritis: Results from a Phase 3 Double blind, Randomized, Placebo-controlled Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl. 10).

DEODHAR, A., BLANCO, R., DOKOUPILOVA, E., VAN DE SANDE, M., HALL, S., WIKSTEN, A., PORTER, B.O., RICHARDS, H. B., HAEMMERLE, S., BRAUN, J. Secukinumab 150 mg Significantly Improved Signs and Symptoms of Nonradiographic Axial Spondyloarthritis: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Study. Poster presented at the Phoenix Rheumatology Association (PRA) Rheumatology Update: Highlights From ACR 2019; January 18, 2020

BEHRENS, F. SEWERIN, P., DE MIGUEL, E., PATEL, Y., BATALOV, A., DOKOUPILOVA, E., KLEINMOND, C., POURNARA, E., SHEKHAWAT, A., JENTZSCH, C., WIEDON, A., BARALIAKOS, X. Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spodyloarthritis: Baseline Results from a Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Behrens F, Sewerin P, De Miguel E, Patel Y, Batalov A, Dokoupilova E, Kleinmond C, Pournara E, Shekhawat A, Jentzsch C, Wiedon A, Baraliakos X. Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).

Genovese M, Lertratanakul A, Anderson J, Papp K, Tillett W, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, Zueger P, Pangan A, Mease P. Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).

Gratacós J, Turkiewicz A, Dokoupilova E, Gellett A, Sprabery A, Geneus V, Constantin A. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).

DE VLAM, K., TAYLOR, P., MEASE, P. J., PELOSO, P., WETZEL, D., BRUN, N., WIENS, B., BRANDTJUERGENS, J., DRESCHER, E., DOKOUPILOVÁ, E., ROWINSKA-OSUCH, A., MARTIN, N. A.-K., BEHRENS, F. Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial. 2022. ISSN 2326-5191.

Behrens F, Taylor P, Mease P, Peloso P, Wetzel D, Brun N, Wiens B, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel- Kader Martin N, de Vlam K. Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9).

Taylor P, Behrens F, Mease P, Wetzel D, Peloso P, Brun N, Wiens B, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel- Kader Martin N, de Vlam K. Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9).

TAYLOR, P., DE VLAM, K., MEASE, P., PELOSO, P., WETZEL, D., LERTRATANAKUL, A., BRUN, N., WIENS, B., BRANDT-JUERGENS, J., DRESCHER, E., DOKOUPILOVA, E., ROWIŃSKA-OSUCH, A., ABDEL-KADER, MARTIN N., BEHRENS, F. Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

DEODHAR, A., SUPRONIK, J., KIVITZ, A., VALENZUELA, G., KAPUR, K., ROHRER, S., DOKOUPILOVA, E., RICHARDS, H., PAVELKA, K. Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

EASTELL, R., LANGDAHL, B., CHUNG, Y., PLEBANSKI, R., CZERWINSKI, E., DOKOUPILOVA, E., SUPRONIK, J., ROSA, J., ROWIŃSKA-OSUCH, A., BAEK, K., URBONIENE, A., AHN, S., RHO, Y., BAN, J. A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

MEASE, P., TAYLOR, P., DE VLAM, K., PELOSO, P., LERTRATANAKUL, A., WETZEL, D., BRUN, N., WIENS, B., BRANDT-JUERGENS, J., DRESCHER, E., DOKOUPILOVA, E., ROWIŃSKA-OSUCH, A., ABDEL-KADER MARTIN, N., BEHRENS, F. Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

KIVITZ, A., MUENSTERMAN, E., KAVANAUGH, A., VAN DER HEIJDE, D., KLIMIUK, P., VALENZUELA, G., DOKOUPILOVA, E., POIRIER, G., SRIVASTAVA, B., DASEN, S., ZHANG, X., TRIVEDI, M., WENG, H., HONG, T., POTHULA, P., BARALIAKOS, X. Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

GOTTLIEB, A., MUENSTERMAN, E., KIVITZ, A., DOKOUPILOVA, E., LERTRATANAKUL, A., HONG, T., CHEN, J., BARALIAKOs, X. Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9)

Deodhar A, Dokoupilova E, Vizcaya C, Sutariya R, Bao W, Kapur K, Rohrer S, Kivitz A. Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9).